Defence Releases Peer-Reviewed Publication of Its Preclinical Data on AccuVAC-D001L In Cell Reports Medicine Journal
Vancouver, British Columbia--(Newsfile Corp. - February 28, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a pre-clinical biotechnology company developing various products for the immune-oncology space, is pleased to announce the publication of its first peer-reviewed study on the potency of AccuVAC-D001L. AccuVAC-D001L is one of Defence's dendritic cell (DC) vaccine products designed to treat established T-cell lymphoma developed from Defence's patented AccumTM technologies. This study, which was published in the prestigious...
2022-02-28 3:15 AM EST
Defence Retains CATO SMS to Advise on Its Phase I Clinical Trial on AccuTOX(TM) for Breast Cancer
Vancouver, British Columbia--(Newsfile Corp. - February 16, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a pre-clinical biotechnology company developing various products for the immune-oncology space, is pleased to announce the establishment of an agreement with CATO SMS, to advise on the submission of its clinical application to Health Canada in order to initiate a Phase I trial using AccuTOXTM against breast cancer. CATO SMS is a consulting firm...
2022-02-16 3:15 AM EST
Defence's Accum(TM)-HPV Vaccine Formulation (AccuVAC-PT009) Activates a 36-Fold Higher Humoral Response Compared to Gardasil-9
Vancouver, British Columbia--(Newsfile Corp. - January 26, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a pre-clinical biotechnology company developing various immune-oncology products, is pleased to announce the development of AccuVAC-PT009, a new protein-based HPV vaccine, leading to a humoral response bypassing Gardasil-9 (Merck) immunogenicity in animals.ACCUMTM is a platform technology 100% owned by Defence Therapeutics. ACCUMTM is an enabling technology as it can be used to enhance the intracellular accumulation of...
2022-01-26 3:15 AM EST
Defence Therapeutics Achieves a Major Milestone and Begins IND-Enabling Testing of Its AccuTOX Lead Compound Against Breast Cancer
Vancouver, British Columbia--(Newsfile Corp. - January 10, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a pre-clinical biotechnology company developing various immune-oncology products, is pleased to announce the start of its final step in GLP studies on its lead anti-cancer AccuTOXTM molecule at Eurofins Advinus Limited prior to initiate its Phase I trial in breast cancer patients. Eurofins Advinus Limited is a leading Drug Discovery and Development Contract Research Organization (CRO)...
2022-01-10 3:15 AM EST
Defence Therapeutics Accum(TM) Boosts by 9-Fold the Delivery Effectiveness of the CRISPR/Cas9 Protein to Target Cells
Vancouver, British Columbia--(Newsfile Corp. - December 13, 2021) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a biotechnology company focused on the development of vaccines and therapeutics against cancer and infectious diseases, is pleased to announce that its AccumTM platform can potently enhance Cas9 delivery in target cells, which would have a significant positive impact on the CRISPR industry. The CRISPR technology offers the potential to transform medicine, enabling both the treatment or...
2021-12-13 3:15 AM EST
Defence Therapeutics Vaccines and Program Development
Vancouver, British Columbia--(Newsfile Corp. - November 30, 2021) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), is a publicly-traded biotechnology company working on engineering the next generation vaccines, Antibody Drug Conjugates, ADC products, and cancer therapeutics using its proprietary AccumTM platform. The core of Defence Therapeutics platform is its AccumTM technology, which enables precision delivery of proteins of pharmacological interest to target cells and increases the intracellular accumulation to these targeted cells. As...
2021-11-30 3:15 AM EST
Defence Therapeutics Cancer Vaccine AccuVac-D001 Manufacturing Targets Melanoma and Breast Cancer
Vancouver, British Columbia--(Newsfile Corp. - November 23, 2021) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a biotechnology company working on cancer therapeutics and infectious disease vaccines is pleased to announce the establishment of an agreement with the Lady Davis Institute cell processing center (CPC) to initiate manufacturing of its AccumTM DC cancer vaccine candidate AccuVAC-D001. This agreement immediately positions Defence's vaccine to be manufactured with the focus on melanoma and breast cancer.The...
2021-11-23 3:15 AM EST
Defence Therapeutics Appoints Dr. Riam Shammaa to Its Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - November 9, 2021) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a biotechnology company working on the development of next generation cancer therapeutics and infectious disease vaccines is pleased to announce the appointment of Dr. Riam Shammaa to its board of directors, effective immediately. Dr. Riam Shammaa, MD, is a pioneer scientist in the fields of cell therapy and biologics and holds several patents in the field. He...
2021-11-09 3:15 AM EST
Defence Therapeutics Reports Successful Completion of Its COVID-19 Vaccine AccuVAC-PT001 Toxicology Studies in Rabbits
Vancouver, British Columbia--(Newsfile Corp. - November 3, 2021) - Defence Therapeutics Inc. (CSE: DTC) (OTC Pink: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a biotechnology company working on the development of next generation cancer therapeutics and infectious disease vaccines is pleased to announce the successful completion of its protein-based COVID-19 vaccine (AccuVAC-PT001) toxicology studies in non-rodent rabbit model. The AccuVAC-PT001 vaccine is an injectable vaccine capable of inducing a powerful and sustainable antibody response in both rodent and non-rodent models....
2021-11-03 3:15 AM EDT
Defence Therapeutics Accum(TM) Variants in Vitro Study Increases the Potency of T-Deruxtecan ADC by 5-Fold on Breast Cancer
Vancouver, British Columbia--(Newsfile Corp. - October 13, 2021) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF ("Defence" or the "Company"), a biotechnology company working on cancer therapeutics and infectious disease vaccines is pleased to announce strong in vitro results of its AccumTM variants on the recent Enhertu® (fam-trastuzumab-deruxtecan-nxki) ADC owned by AstraZeneca and Daiichi Sankyo. Defence has successfully selected and tested 5 AccumTM variants to the T-deruxtecan ADC Therapeutic. The 5 selected Accum-T-deruxtecan increases the potency...
2021-10-13 3:15 AM EDT
Defence Therapeutics Prepares for Phase I Trial to Test Its DC Cancer Vaccine, AccuVAC-D002, Against Melanoma
Vancouver, British Columbia--(Newsfile Corp. - October 6, 2021) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a biotechnology company working on cancer therapeutics and infectious disease vaccines, is finalizing all required steps in preparation to a pre-IND meeting to initiate a phase I trial against melanoma using its DC cancer vaccine candidate AccuVAC-D002.Defence has successfully exploited the use of its AccumTM technology platform to develop a large pipeline of products in immune-oncology and...
2021-10-06 3:15 AM EDT
Defence Therapeutics to Finalize Its Objectives to Initiate a Phase I Trial Against Breast Cancer
Vancouver, British Columbia--(Newsfile Corp. - September 29, 2021) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a biotechnology Company working on cancer therapeutics and infectious diseases vaccines, is pleased to announce that it will be conducting a series of final studies to complete all requirement needed to initiate a Phase I trial for one of its leading AccuTOX candidate against breast cancer. The AccumTM technology platform was initially designed to enhance...
2021-09-29 3:15 AM EDT
Defence Therapeutics Successfully Engineered and Tested a Novel Intranasal COVID-19 Vaccine Formulation in Animals
Vancouver, British Columbia--(Newsfile Corp. - September 20, 2021) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a biotechnology company working on cancer therapeutics and infectious disease vaccines is pleased to announce the development of a "non-injectable" second generation COVID vaccine, AccuVAC-IN002, for intranasal delivery. Vaccination against SARS2-COVID was initially efficient at slowing down viral spreading across the globe. However, the arrival of new and more infectious strains is challenging to current...
2021-09-20 3:15 AM EDT
Defence Therapeutics Success in Testing Its COVID-19 AccuVAC-PT001 Vaccine in a Non-Rodent Model
Vancouver, British Columbia--(Newsfile Corp. - September 14, 2021) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a biotechnology company working on cancer therapeutics and infectious disease vaccines, is pleased to announce the completion of a non-GLP study on rabbits demonstrating a potent humoral response with titer reaching 1:43 000 000 per average without any signs of toxicity. Defence has previously developed and tested its AccuVAC-PT001 vaccine in mice. This vaccine is highly...
2021-09-14 3:15 AM EDT
Defence Therapeutics Development Program to Engineer a New HPV Vaccine Initiated
Vancouver, British Columbia--(Newsfile Corp. - September 7, 2021) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a biotechnology company working on ADC therapeutics for cancer targeting with its AccumTM technology and cancer vaccine therapeutics and infectious disease vaccines, is pleased to announce the establishment of a high priority program to develop a novel HPV-targeting vaccine for cervical cancer with it's AccumTM technology. Currently there are more than 40 types of HPV strains capable...
2021-09-07 3:15 AM EDT
Defence Therapeutics Files Acid-Based Hydrogels USA Provisional Patent Application
Vancouver, British Columbia--(Newsfile Corp. - August 31, 2021) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a biotechnology company working on ADC therapeutics for cancer targeting with its AccumTM technology and cancer vaccine therapeutics and infectious disease vaccines is pleased to announce the expansion of its patent portfolio through the filing of its AccumTM technology-based USA Provisional Patent Application named "Steroid Acid-Based Hydrogels". Hydrogels are cross-linked polymer networks that can swell and retain...
2021-08-31 3:15 AM EDT
Defence Therapeutics Selects the Best Eight Accum(TM) Variants to Optimize Its ADC Therapeutic
Vancouver, British Columbia--(Newsfile Corp. - August 18, 2021) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company"), is pleased to announce, that after a detailed and rigorous selection process, very strong and promising results of its bests AccumTM variants has been identified. Defence's has tested 43 AccumTM variants conjugated to T-DM1 with a low conjugation ratio (1-4 AccumTM per T-DM1) in order to select the best ones to pursue our selection of the optimized Accum-T-DM1 conjugate based on in...
2021-08-18 3:15 AM EDT
Defence Therapeutics Receives DTC Eligibility
Vancouver, British Columbia--(Newsfile Corp. - August 11, 2021) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company"), a biotechnology company working on cancer therapeutics and infectious disease vaccines, is pleased to announce that the Company received its DTC eligibility. Defence's common shares are now eligible for book entry and depository services of the Depository Trust Company (DTC), which facilitate electronic clearing and settlement of its common shares in the United States. "We are pleased to have received DTC eligibility...
2021-08-11 4:00 PM EDT
Defence Therapeutics Signs an Agreement with Biopharma Excellence, a Pharmalex GmbH Company, to Maximize and Strategize the Development of Its Accum(TM) Platform and Clinical Trials
Vancouver, British Columbia--(Newsfile Corp. - August 4, 2021) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company"), a biotechnology company working on cancer therapeutics and infectious disease vaccines is pleased to announce the agreement with the German renowned pharmaceutical consulting and advisory company, Pharmalex GmbH, through Biopharma Excellence. With more than 35,000 successful projects completed, Pharmalex GmbH is a leading provider of specialized services for the pharmaceuticals, biotech and medical device industries that prioritize compliance. Biopharma Excellence, a Pharmalex...
2021-08-04 3:15 AM EDT
The Antibody Response Induced by Defence Therapeutics AccuVAC-PT001 Vaccine Cross-Reacts with All Tested SARS-CoV-2 Variants
Vancouver, British Columbia--(Newsfile Corp. - July 6, 2021) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company"), a biotechnology company working on cancer therapeutics and infectious disease vaccines is pleased to announce, as an update of it's May 31st, 2021 press release, that sera isolated from AccuVAC-PT001-vaccinated animals cross-reacts with the Spike protein of several SARS-CoV-2 variants. More specifically, generated antibodies bind the RBD domains (responsible for binding human ACE2 receptors in human cells) of the Californian, South African,...
2021-07-06 3:15 AM EDT